This is yet another reminder that all next-big-thing investments need time to mature.
News & Analysis: Zynerba Pharmaceuticals
In a dismal year for most marijuana stocks, these three winners have bucked the trend.
Investors appear to be worried about potential safety issues with its cannabinoid gel.
The stock cooled off along with its cannabis-based peers.
The marijuana craze has hit this clinical-stage pharmaceutical company.
These biotech stocks have at least quadrupled in just over six months this year.
Only around 1 in 4 marijuana stocks ended the second quarter higher.
Seven cannabis stocks doubled, and nearly two-thirds of all pot stocks ended the period higher.
A new patent is generating excitement among investors for this clinical-stage biotech stock.
The bottom line: a whole lot of uncertainty.